Novavax

Novavax is an American vaccine development company headquartered in Gaithersburg, Maryland, with additional facilities in Rockville, Maryland and Uppsala, Sweden. Novavax is focused on the discovery, development and commercialization of vaccines to prevent serious infectious diseases.

History

Novavax was founded in 1987. The company's proprietary technology platform combines the power and speed of genetic engineering to efficiently produce highly immunogenic nanoparticles designed to address urgent global health needs.

Products

Novavax has several vaccines in development, including NVX-CoV2373, a vaccine candidate engineered from the genetic sequence of the SARS-CoV-2, the virus that causes COVID-19 disease. NVX-CoV2373 was created using Novavax' recombinant nanoparticle technology and includes Novavax' proprietary Matrix-M™ adjuvant.

Clinical Trials

Novavax has conducted several clinical trials for its vaccine candidates, including a pivotal Phase 3 trial in the United Kingdom and two ongoing Phase 2 studies that began in August 2020 - a Phase 2b trial in South Africa, and a Phase 1/2 continuation in the United States and Australia.

Partnerships

Novavax has formed significant partnerships to increase its global manufacturing capacity. This includes an agreement with Serum Institute of India, the world's largest vaccine manufacturer, to develop and commercialize NVX-CoV2373.

See Also

• Vaccine
• COVID-19
• Clinical trial
• Serum Institute of India

This article is a medical stub. You can help WikiMD by expanding it!
Most recent articles Ongoing trials	Wikipedia

• Error creating thumbnail:
  Novavax logo
• Novavax Building
  Novavax Building
• Novavax research and development
  Novavax research and development
• Novavax
  Novavax
• Larry Hogan at Novavax campus
  Larry Hogan at Novavax campus

• Novavax Building
  Novavax Building
• Novavax Research and Development
  Novavax Research and Development
• Novavax
  Novavax
• Larry Hogan at Novavax Campus
  Larry Hogan at Novavax Campus